Sky Century Investment (SKYI) Net Income towards Common Stockholders (2024 - 2026)
Sky Century Investment (SKYI) posted quarterly Net Income towards Common Stockholders of -$4347.0 for Q2 2026, up 66.68% year-over-year from -$2608.0 in Q2 2025, and down 173.52% quarter-over-quarter from $5913.0 in Q1 2026.
Sky Century Investment (SKYI) Net Income towards Common Stockholders (2024 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has reported Net Income towards Common Stockholders for 3 consecutive years, with -$4347.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders rose 66.68% year-over-year to -$4347.0; the TTM figure through May 2026 stood at -$62452.0 (up 34.97% YoY), while the FY2025 annual figure was -$117225.0, down 60.76% from the prior year.
- Net Income towards Common Stockholders retreated to -$4347.0 in Q2 2026 per SKYI's latest filing, from $5913.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $5913.0 in Q1 2026 and bottomed at -$41628.0 in Q4 2024.
- Historically, Net Income towards Common Stockholders has averaged -$20853.7 across 3 years, with a median of -$20677.5 in 2024.
- Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders slumped 145.07% — and 2026, when it jumped 122.11%.
- Sky Century Investment's Net Income towards Common Stockholders stood at -$41628.0 in 2024, then surged by 32.23% to -$28213.0 in 2025, then soared by 84.59% to -$4347.0 in 2026.
- Business Quant data shows SKYI's Net Income towards Common Stockholders at -$4347.0 in Q2 2026, $5913.0 in Q1 2026, and -$28213.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Sky Century Investment | 393,547.71 | 393,283.71 | 26,045.00 | -4,347.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -4,347.00 |
| Feb 28, 2026 | 5,913.00 |
| Nov 30, 2025 | -28,213.00 |
| Aug 31, 2025 | -35,805.00 |
| May 31, 2025 | -13,047.00 |
| Feb 28, 2025 | -26,745.00 |
| Nov 30, 2024 | -41,628.00 |
| Aug 31, 2024 | -14,610.00 |
| May 31, 2024 | -14,149.00 |
| Feb 29, 2024 | -35,906.00 |